|1.||Kosel, David: 1 article (07/2015)|
|2.||Kalkhof, Stefan: 1 article (07/2015)|
|3.||Beck-Sickinger, Annette G: 1 article (07/2015)|
|4.||von Bergen, Martin: 1 article (07/2015)|
|5.||Ahrens, Verena M: 1 article (07/2015)|
|6.||Rennert, Robert: 1 article (07/2015)|
|7.||Weber, Lutz: 1 article (07/2015)|
|8.||Kostelnik, Katja B: 1 article (07/2015)|
|9.||Böhme, David: 1 article (07/2015)|
|10.||Basile, Giovanna: 1 article (05/2009)|
07/10/2015 - "For selective cancer cell targeting, here the coupling of a synthetic cytolysin to the hY1-receptor preferring peptide [F(7),P(34)]-neuropeptide Y (NPY) using a labile disulfide linker is described. "
01/01/1986 - "Conjugation of the chemotactic peptide f-Met-Leu-Phe (fMLP) to tumor-directed antibodies yields compounds active in vitro and in vivo. "
12/01/1987 - "Although exposure of neutrophils to TNF alone caused no superoxide anion production, it enhanced the O2- production in response to the chemotactic peptide, f-methionyl-leucyl-phenylalanine (FMLP) or the tumor promotor, phorbol myristate acetate, by as much as 278%. "
06/01/1987 - "Larger volume was shown to correlate with increased superoxide release with either the chemotactic peptide F-met-leu-phe (FMLP) or the tumor promotor phorbol myristate acetate (PMA). "
10/01/1982 - "In contrast, release of histamine stimulated by the formyl methionine containing peptide f-met-leu-phe, the calcium ionophore A23187, and the tumor-promoting phorbol diester 12-O-tetradecanoylphorbol-13-acetate was not inhibited by 24-hr incubation with the potent glucocorticoid dexamethasone. "
|2.||Psoriasis (Pustulosis Palmaris et Plantaris)
01/01/1987 - "In the active phase of pustular psoriasis, the neutrophil chemiluminescence response to the chemotactic peptide f-met-leu-phe and to phorbol myristate acetate was enhanced and correlated to the development of pustules, whereas cells from psoriasis vulgaris patients showed normal chemiluminescence response. "
01/01/1986 - "PMN of 17 patients with psoriasis and 13 patients with AD with mild to moderate disease activity were stimulated with a chemotactic peptide (f-met-phe), zymosan activated serum (ZAS), zymosan particles and phorbol myristate acetate. "
|3.||Lassa Fever (Fever, Lassa)
09/01/1991 - "Plasma from patients with Lassa fever also profoundly modulates the amount of superoxide generated by normal neutrophils in response to the chemotactic peptide f-met-leu-phe, suggesting the inhibitor(s) has global effects on cellular function. "
10/01/1989 - "Thirteen of 15 samples from patients in the acute phase of Lassa fever profoundly inhibited the amount of superoxide generated by normal neutrophils in response to the chemotactic peptide, f-met-leu-phe (FMLP) (mean superoxide generated = 54.7 +/- 6.1% of control). "
|4.||Prostatic Neoplasms (Prostate Cancer)
01/01/2003 - "Excretion of part of the prothrombin activation peptide F(1+2) (called here iF2), interleukin-6 (IL-6), the bone turnover marker deoxypyridinoline (DpD), and vascular endothelial growth factor (VEGF) were quantitated in spot urine samples collected from 37 men with hormone-refractory prostate cancer. "
|6.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|7.||Interleukin-6 (Interleukin 6)
|9.||Prothrombin (Factor II)